| abstract |
The present invention relates to a polypeptide comprising a crystallizable fragment (Fc) region of IgG for use in the prevention or treatment of a disease, specifically a disease affecting the central nervous system. The polypeptide is administered topically to the compartment, specifically the central nervous system. The Fc region contains the mutations I253N and H435Q, which result in a reduced affinity for the neonatal Fc receptor (FcRn), as well as H at position 310, resulting in an increase in brain-to-serum concentration of the polypeptide. |